MAM
ACRS icon

Marquette Asset Management’s Aclaris Therapeutics ACRS Stock Holding History

Marquette Asset Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-57,911
Closed -$144K – 148
2024
Q4 		$144K Sell
57,911
-26,068
-31% -$64.9K 0.02% 110
2024
Q3 		$96.6K Hold
83,979
– – 0.02% 134
2024
Q2 		$92.4K Hold
83,979
– – 0.02% 115
2024
Q1 		$104K Buy
+83,979
New +$100K 0.02% 114

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Marquette Asset Management's ACRS Position: Q1 2025 in Review

Marquette Asset Management sold out of Aclaris Therapeutics (ACRS) in Q1 2025, closing a stake of 57,911 shares — an estimated $144K sold.

Marquette Asset Management first reported a position in ACRS in Q1 2024 and held it in 4 quarters. The position peaked at $144K in Q4 2024. 109 funds tracked by Wall St. Rank hold ACRS as of Q1 2025.

  • Marquette Asset Management reported no remaining Aclaris Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Marquette Asset Management sold 57,911 Aclaris Therapeutics shares in Q1 2025, an estimated $144K.
  • Marquette Asset Management first reported a position in Aclaris Therapeutics in Q1 2024 and held it in 4 quarters.
  • Marquette Asset Management's Aclaris Therapeutics position peaked at $144K in Q4 2024.
  • 109 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2025.

Based on Marquette Asset Management's 13F filing for Q1 2025, filed 9 Apr 2025.